Board of Directors


CEO, Member of the Board
ulrika.warpmanberglund@oxcia.se


Chairman of the Board
jan.zetterberg@oxcia.se
Thomas Helleday
CSO, Member of the Board
thomas.helleday@oxcia.se
Jan Benjaminson
Member of the Board
jan.benjaminson@oxcia.se

Get to know us


CEO, Member of the Board
ulrika.warpmanberglund@oxcia.se

Ulrika Warpman Berglund is a Pharmacist and has a PhD in Pharmacology. She joined Pharmacia in 1997, where she worked as a scientist, section head and project leader. In 2000 she joined Biovitrum as project leader as well as group leader.

In 2009, Ulrika left Sweden to join Prosidion Ltd in Oxford, UK, where she successfully established a pharmacology department and was part of the Research steering group. Ulrika has proven strong leader qualities and drug discovery know how in a number of multi-disciplinary project teams, pharmacology teams, steering teams and during restructuring processes and thereby gained confidence in her ability of strategic thinking, as well as her ability to set up visions, organise and establish new teams, communicate, and collaborate. She has directed business goals and together with her teams significantly contributed towards achieving them. Ulrika has successfully managed research projects leading to outlicensing of projects and developing of clinical candidates. In 2012, she joined Professor Helleday at Karolinska Institute to perform drug discovery in an academic setting.


Chairman of the Board
jan.zetterberg@oxcia.se

thoJan Zetterberg finished law studies in 1975 after which he worked for the Swedish Court system until 1979. He joined AstraZeneca (Astra) in 1983 where he held several roles such as Legal Counsel, Senior Counsel, Vice President, Strategy, Intellectual Property and since 1999 as Assistant General Counsel.

Jan Zetterberg provided global legal support in all areas of business including corporate functions, R&D, Operations, and Business Development. In addition he was appointed line manager for AstraZeneca Trademarks group in 2008. Jan Zetterberg retired from AstraZeneca end 2011. He started Zedur AB in January 2012 to provide consultancy services in the legal and compliance area supporting primarily small to medium size Life Science industry. He became Partner and Chairman of the Board of Zelibra AB in January 2012. Zelibra AB is a Swedish company offering the services of internationally experienced consultants to the life science industry. Its mission is to help bring life science innovations to the right market in a timely and cost-effective manner. In January 2014 Jan Zetterberg was elected Chairman of the Board of ExThera AB.


Member of the Board
thomas.helleday@oxcia.se

Thomas Helleday is Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, where he heads a large multidisciplinary translational research group focusing on understanding DNA damage response biology and translating the findings into novel anti-cancer treatments concepts and drugs.  The group was first to demonstrate the synthetic lethality concept for treating cancer by showing homologous recombination defective cancers (e.g., BRCA) were sensitive to PARP inhibitors. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award (2005) and ERC advanced grants (2010 and 2016).

Prof Helleday is a honorary professor at University of Sheffield where he previously were Cancer Centre Director and has previous professorial chairs at University of Oxford and Stockholm University

Eva Sjökvist Saers is a Pharmacist and has a PhD from the Faculty of Pharmacy, University of Uppsala. Eva joined the Astra group (Astra Pain Control and AstraZeneca) as Director within pharmaceutical research and development, with responsibility of e.g. product development, manufacturing to clinical trials and tech transfer to large scale manufacturing. For more than 15 years Eva was the head and CEO of APL (Apotek Produktion & Laboratorier AB), a pharmaceutical company with more than 500 employess and a revenue of SEK 1,4 billion. APL has the commission from the state to develop and manufacture pharmaceuticals for patients with special needs. APL is also a CDMO (Contract Development and Manufacturing Organisation) that supports life science companies with drug development and manufacturing services.  Eva is today active in boards in life science as a board member in e.g. Recipharm AB, IDL Biotech AB and Bluefish Pharmaceuticals AB. Eva is the chairman of Swelife, a strategic innovation program appointed by the government. She is the former chairman of the Swedish Society of Pharmaceutical Sciences (Apotekarsocieteten), former vice chairman of SwedenBIO, the national association of the life science industry, and former boardmember of KIHAB (Karolinska Institutet Holding AB).

Jan Benjaminson
Member of the Board
jan.benjaminson@oxcia.se

Jan Benjaminson has a MSc in Business and economics from Lund University. He has long standing experience from IPO, financing and capital raising as member of the board, CEO and CFO from various listed and unlisted software companies in Sweden. Jan specialties during the last twenty years are more and more concentrating on business development, building up organizations, focusing operations, turnarounds, seeking capital to expansions and IPOs (Initial Public Offerings). Jan has published more than 50 quarterly report to the financial market from company listed and traded in Sweden and have been involved in 12-15 funding’s, capital raise, financing’s and IPO’s.The first twelve year after his degree from University of Lund he was working in traditional industries. From year 2000 he has focused on SME and mainly in tech companies. By today he has a full-time employment as CFO in an esports company, G-Loot Global Esport and besides Oxcia assignment, additional three board assignments; Mid cap listed Starbreeze and two private owned gaming companies.